Simplify Logo

Full-Time

Senior Research Associate

In Vitro Assay Development & High-throughput Screening

Confirmed live in the last 24 hours

Remix Therapeutics

Remix Therapeutics

51-200 employees

Develops mRNA-based treatments for rare diseases

Biotechnology
Healthcare

Mid, Senior

Belmont, MA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Google Cloud Platform
Requirements
  • BS, M.Sc. or equivalent in biochemistry, biophysics, or a related discipline with 4-6+ years of experience working in a pharmaceutical/biotechnology laboratory setting
  • Experience running multi-well plate-based *in vitro* assays with fluorescent/luminescent readouts (e.g. TR-FRET, FP) at various scales
  • Experience working with laboratory automation, HTS, Hit-to-Lead, and compound management workflows is required
  • Familiarity with various biochemical and biophysical techniques (including cutting-edge technologies e.g., SPR/GCI, MST, DSF, etc.) is desired
Responsibilities
  • Execute high-throughput screening campaigns with small molecule libraries
  • Design and develop *in vitro* assays to screen/profile the binding and complex kinetics of small molecule compounds to large protein complexes
  • Evaluate and implement novel biochemical and biophysical technologies for target and hit discovery
  • Interpret, present, and report research findings in an open and timely manner
  • Build and maintain productive relationships with colleagues in biomolecular sciences, biology, and chemistry

Remix Therapeutics focuses on developing treatments for rare and challenging diseases, particularly targeting rare cancers and genetic disorders. Their main product, REM 422, is an oral small molecule that works by degrading messenger RNA (mRNA) to stop the production of harmful proteins associated with these diseases. Currently, REM 422 is undergoing Phase 1 clinical trials for Adenoid Cystic Carcinoma and Acute Myeloid Leukemia, and it has received Orphan Drug Designation from the FDA, which offers benefits for drugs treating rare conditions. Unlike many competitors, Remix Therapeutics emphasizes a strong research and development approach, heavily investing in scientific research and forming partnerships with larger pharmaceutical companies. The company's goal is to provide new hope and effective treatments for patients suffering from serious illnesses, driven by the personal experiences of its founders and team.

Company Stage

Series B

Total Funding

$224.7M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

4%

1 year growth

6%

2 year growth

21%
Simplify Jobs

Simplify's Take

What believers are saying

  • The collaboration with Roche, potentially worth up to $1 billion, underscores the high commercial potential and validation of Remix's technology.
  • Recent leadership appointments, such as Dr. Maria Koehler and Dr. Dominic Reynolds, bring extensive industry experience, enhancing the company's strategic direction and clinical development capabilities.
  • Successful preclinical data and ongoing Phase 1 trials for REM 422 indicate promising therapeutic potential, which could lead to significant advancements in treating rare cancers and genetic disorders.

What critics are saying

  • The high dependency on the success of REM 422 means that any setbacks in clinical trials could severely impact the company's prospects.
  • The competitive landscape in RNA-based therapies is intensifying, with larger pharmaceutical companies potentially overshadowing Remix's innovations.

What makes Remix Therapeutics unique

  • Remix Therapeutics leverages its proprietary REMaster™ platform to uniquely target RNA processing, setting it apart from traditional biotech approaches.
  • The company's focus on rare diseases and conditions with significant unmet medical needs differentiates it from competitors who target more common ailments.
  • The Orphan Drug Designation for REM 422 provides market exclusivity and tax benefits, giving Remix a competitive edge in the rare disease market.